Jonsson Comprehensive Cancer Center
ucla.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
396
Active
116
Phase 3
19
Total enrollment
437,107
Pipeline matrix
Showing 40 of 87 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| temozolomide | — | — | — | 10 | |||
| Ferumoxytol | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | 10 | |||
| carboplatin | — | — | 13 | ||||
| cisplatin | — | — | — | 8 | |||
| Fluorouracil | — | — | 7 | ||||
| Durvalumab | — | — | — | — | 5 | ||
| Leucovorin | — | — | — | 4 | |||
| Oxaliplatin | — | — | — | 4 | |||
| Lutetium Lu 177 Vipivotide Tetraxetan | — | — | — | — | — | 3 | |
| docetaxel | — | — | — | 6 | |||
| fludarabine phosphate | — | — | — | — | 9 | ||
| Osimertinib | — | — | — | — | — | 3 | |
| Tremelimumab | — | — | — | — | — | 3 | |
| Irinotecan | — | — | — | 3 | |||
| Apalutamide | — | — | — | — | — | 2 | |
| Fisetin | — | — | — | — | — | 2 | |
| Zimberelimab | — | — | — | — | 2 | ||
| Anastrozole | — | — | — | — | — | 2 | |
| Abemaciclib | — | — | — | — | — | 2 | |
| trametinib | — | — | — | — | — | 2 | |
| cyclophosphamide | — | — | 10 | ||||
| paclitaxel | — | — | — | 9 | |||
| trastuzumab | — | — | 8 | ||||
| Leucovorin Calcium | — | — | — | 3 | |||
| aldesleukin | — | — | — | — | 6 | ||
| bevacizumab | — | — | — | — | — | 5 | |
| dasatinib | — | — | — | — | 4 | ||
| dendritic cell vaccine therapy | — | — | — | — | 3 | ||
| NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | — | — | — | — | 3 | ||
| Liposome-encapsulated Daunorubicin-Cytarabine | — | — | — | — | 2 | ||
| Letrozole | — | — | — | — | 2 | ||
| everolimus | — | — | — | — | — | 2 | |
| Telisotuzumab Vedotin | — | — | — | — | — | 1 | |
| Antiandrogen Therapy | — | — | — | — | — | 1 | |
| Ropeginterferon Alfa-2B | — | — | — | — | — | 1 | |
| Abiraterone Acetate | — | — | — | — | — | 1 | |
| Leuprolide Acetate | — | — | — | — | — | 1 | |
| Enasidenib Mesylate | — | — | — | — | — | 1 | |
| Necitumumab | — | — | — | — | — | 1 |
47 more active programs hidden
Next readouts
- 2023-12-05
- 2024-01-31
- 2024-09-01
- 2024-09-23
- 2024-10-11
- 2025-06-24
- 2025-12-01
- 2026-01-11
- 2026-01-27
- 2026-07-01
Top conditions
- Prostate Cancer30
- Lymphoma24
- Breast Cancer22
- Lung Cancer21
- Leukemia17
- Unspecified Adult Solid Tumor, Protocol Specific16
- Brain and Central Nervous System Tumors16
- Prostate Adenocarcinoma12
Frequently asked questions about Jonsson Comprehensive Cancer Center
- How many clinical trials does Jonsson Comprehensive Cancer Center have on ClinicalTrials.gov?
- Jonsson Comprehensive Cancer Center is listed as the lead sponsor on 396 clinical trials in ClinicalTrials.gov, 116 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Jonsson Comprehensive Cancer Center's trials are in Phase 3?
- 19 of Jonsson Comprehensive Cancer Center's trials are in Phase 3, spread across 87 active drug programs.
- What therapeutic areas does Jonsson Comprehensive Cancer Center focus on?
- Jonsson Comprehensive Cancer Center's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Lymphoma, Breast Cancer, Lung Cancer, Leukemia.
- When are Jonsson Comprehensive Cancer Center's next clinical trial readouts?
- Jonsson Comprehensive Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer”, expected around 2023-12-05.